Joshua C Anderson Selected Research

Myristoylated Alanine-Rich C Kinase Substrate

11/2020	A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma.
6/2019	Myristoylated alanine-rich C-kinase substrate effector domain phosphorylation regulates the growth and radiation sensitization of glioblastoma.
3/2017	MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell lines.
3/2015	Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivity.
6/2012	MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joshua C Anderson Research Topics

Disease

30	Neoplasms (Cancer) 01/2023 - 10/2005
7	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 06/2012
4	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2014
3	Carcinogenesis 01/2021 - 05/2016
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020 - 03/2015
2	Neuroblastoma 06/2022 - 06/2021
2	Breast Neoplasms (Breast Cancer) 01/2021 - 04/2019
2	IGA Glomerulonephritis (IGA Nephropathy) 05/2020 - 11/2017
2	Carcinoma (Carcinomatosis) 01/2020 - 10/2019
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 10/2019
2	Neoplasm Metastasis (Metastasis) 04/2019 - 04/2017
2	Renal Cell Carcinoma (Grawitz Tumor) 04/2017 - 01/2015
2	Infections 07/2015 - 01/2014
1	Neurofibrosarcoma (MPNST) 01/2023
1	Leukemia 01/2023
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Melanoma (Melanoma, Malignant) 01/2022
1	Heart Failure 01/2022
1	Kidney Diseases (Kidney Disease) 11/2021
1	Residual Neoplasm 01/2021
1	Hepatoblastoma 01/2021
1	Adenocarcinoma of Lung 01/2021
1	Inflammation (Inflammations) 05/2020
1	Body Weight (Weight, Body) 01/2020
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020
1	Ventricular Remodeling 01/2020
1	Squamous Cell Carcinoma of Head and Neck 01/2020
1	Colorectal Neoplasms (Colorectal Cancer) 10/2019
1	Wilms Tumor (Wilm's Tumor) 09/2019
1	Ovarian Neoplasms (Ovarian Cancer) 02/2018

Drug/Important Bio-Agent (IBA)

17	Phosphotransferases (Kinase)IBA 01/2023 - 01/2014
8	Proteins (Proteins, Gene)FDA Link 06/2022 - 10/2005
7	Peptides (Polypeptides)IBA 11/2020 - 03/2007
5	Myristoylated Alanine-Rich C Kinase SubstrateIBA 11/2020 - 06/2012
3	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 06/2022 - 03/2017
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2023 - 09/2019
2	AZD1208IBA 01/2023 - 01/2021
2	Small Interfering RNA (siRNA)IBA 01/2023 - 06/2021
2	Focal Adhesion Protein-Tyrosine KinasesIBA 06/2022 - 09/2019
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022 - 02/2018
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 01/2020
2	Phospholipids (Phosphatides)FDA LinkGeneric 11/2020 - 06/2019
2	Temozolomide (Temodar)FDA LinkGeneric 11/2020 - 06/2014
2	AutoantigensIBA 05/2020 - 11/2017
2	galactosyl-deficient IgA1IBA 05/2020 - 11/2017
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 06/2012
2	Transcription Factors (Transcription Factor)IBA 10/2019 - 07/2015
2	tyrosine receptor (receptor, tyrosine)IBA 06/2019 - 03/2015
2	Biomarkers (Surrogate Marker)IBA 04/2019 - 01/2014
2	Tyrosine (L-Tyrosine)FDA Link 04/2017 - 07/2015
1	Neuregulin-1 (Neuregulin 1)IBA 01/2023
1	Mitogen-Activated Protein KinasesIBA 01/2023
1	Trifluoperazine (Stelazine)FDA LinkGeneric 01/2023
1	AZD 8931IBA 01/2023
1	Calmodulin (Calcium-Dependent Activator Protein)IBA 01/2023
1	saracatinibIBA 01/2023
1	TOR Serine-Threonine KinasesIBA 01/2023
1	Canertinib (CI 1033)IBA 01/2023
1	6- (4- (3- (methylsulfonyl)benzylamino)- 5- (trifluoromethyl)pyrimidin- 2- ylamino)- 3,4- dihydroquinolin- 2(1H)- oneIBA 06/2022
1	ruxolitinibIBA 01/2022
1	Tamoxifen FDA LinkGeneric 01/2022
1	Glycogen Synthase Kinase 3IBA 01/2022
1	Protein Isoforms (Isoforms)IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Cre recombinaseIBA 01/2022
1	Platelet-Derived Growth FactorIBA 11/2021
1	Strap proteinIBA 06/2021
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2021
1	Trastuzumab (Herceptin)FDA Link 01/2021
1	Ado-Trastuzumab EmtansineIBA 01/2021
1	MicroRNAs (MicroRNA)IBA 01/2021
1	proto-oncogene proteins pimIBA 01/2021
1	Phosphatidylinositols (Phosphatidylinositol)IBA 11/2020
1	Antigen-Antibody Complex (Immune Complex)IBA 05/2020
1	AutoantibodiesIBA 05/2020
1	InterleukinsIBA 05/2020
1	CytokinesIBA 05/2020
1	Leukemia Inhibitory FactorIBA 05/2020
1	Oncostatin MIBA 05/2020
1	8- dibenzothiophen- 4- yl- 2- morpholin- 4- yl- chromen- 4- oneIBA 01/2020
1	olaparibIBA 01/2020
1	Insulin (Novolin)FDA Link 01/2020
1	Insulin ReceptorIBA 01/2020
1	Cetuximab (Erbitux)FDA Link 10/2019
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 09/2019
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 06/2019
1	TensinsIBA 06/2019
1	Syk KinaseIBA 04/2019
1	fostamatinibIBA 04/2019
1	Cell Surface ReceptorsIBA 02/2018
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 02/2018
1	PhosphotyrosineIBA 02/2018
1	Gefitinib (Iressa)FDA Link 02/2018
1	SialyltransferasesIBA 02/2018
1	EnzymesIBA 02/2018
1	Glucose (Dextrose)FDA LinkGeneric 01/2018

Therapy/Procedure

16	Therapeutics 01/2023 - 03/2007
4	Drug Therapy (Chemotherapy) 01/2021 - 01/2018
1	Radiotherapy 01/2022